0.014124 0.008155 0.000000 0.000000 0.016309 0.000000 0.000000 0.000000 0.004789 0.00000 0.00000 0.00000 Herman, M.D. Lehtio, L. Arrowsmith, C.H. Berglund, H. Busam, R.D. Collins, R. Dahlgren, L.G. Edwards, A.M. Flodin, S. Flores, A. Graslund, S. Hammarstrom, M. Johansson, I. Kallas, A. Karlberg, T. Kotenyova, T. Moche, M. Nilsson, M.E. Nyman, T. Persson, C. Sagemark, J. Svensson, L. Thorsell, A.G. Tresaugues, L. van den Berg, S. Weigelt, J. Welin, M. Nordlund, P. Structural Genomics Consortium (SGC) http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 18 90.00 90.00 120.00 70.800 70.800 208.800 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking H2 O 18.015 WATER non-polymer C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C5 H11 N O2 S 149.211 y METHIONINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking O4 S -2 96.063 SULFATE ION non-polymer C4 H9 N O3 119.119 y THREONINE L-peptide linking C11 H12 N2 O2 204.225 y TRYPTOPHAN L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking NE FEBS Lett. FEBLAL 0165 0014-5793 582 3590 10.1016/J.FEBSLET.2008.09.028 18812174 Completing the Family Portrait of the Anti- Apoptotic Bcl-2 Proteins: Crystal Structure of Human Bfl-1 in Complex with Bim. 2008 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 100 1 MIRRORS CCD 2007-09-27 ADSC CCD DIAMOND (111), GE(220) SINGLE WAVELENGTH M x-ray 1 0.934000 1.0 ID14-1 ESRF 0.934000 SYNCHROTRON ESRF BEAMLINE ID14-1 17246.617 BCL-2-RELATED PROTEIN A1 RESIDUES 1-149 1 man polymer 3117.497 BCL-2-LIKE PROTEIN 11 RESIDUES 141-165 1 man polymer 96.063 SULFATE ION 1 syn non-polymer 18.015 water 38 nat water PROTEIN BFL-1, HEMOPOIETIC-SPECIFIC EARLY RESPONSE PROTEIN, PROTEIN GRS, BCL-2A1, A1 BCL2-INTERACTING MEDIATOR OF CELL DEATH no no SMTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVEKNLKSCLDNVNVVSVDTARTLFNQVMEKEF EDGIINWGRIVTIFAFEGILIKKLLRQQIAPDVDTYKEISYFVAEFIMNNTGEWIRQNGGWENGFVKKFE SMTDCEFGYIYRLAQDYLQCVLQIPQPGSGPSKTSRVLQNVAFSVQKEVEKNLKSCLDNVNVVSVDTARTLFNQVMEKEF EDGIINWGRIVTIFAFEGILIKKLLRQQIAPDVDTYKEISYFVAEFIMNNTGEWIRQNGGWENGFVKKFE A polypeptide(L) no no DMRPEIWIAQELRRIGDEFNAYYAR DMRPEIWIAQELRRIGDEFNAYYAR B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n HUMAN sample 9606 HOMO SAPIENS 469008 ESCHERICHIA COLI BL21(DE3) R3 PRARE PNIC-BSA4 HUMAN sample 9606 HOMO SAPIENS 469008 ESCHERICHIA COLI BL21(DE3) R3 PRARE PNIC-BSA4 2 2.48 50.4 NONE VAPOR DIFFUSION, HANGING DROP 5.8 0.1M BIS, TRIS PH 5.8, 2M AMSO4 293 exptl_crystal_grow pdbx_database_status reflns repository Initial release Advisory Refinement description Version format compliance Data collection Experimental preparation Other 1 0 2008-02-05 1 1 2011-07-13 1 2 2019-09-25 _exptl_crystal_grow.method _exptl_crystal_grow.temp _pdbx_database_status.status_code_sf _reflns.pdbx_Rmerge_I_obs HUMAN BIR2 DOMAIN OF BACULOVIRAL INHIBITOR OF APOPTOSIS REPEAT-CONTAINING 1 (BIRC1 CRYSTAL STRUCTURE OF A BHRF-1 : BIM BH3 COMPLEX PDBE Y PDBE 2008-01-23 REL REL SO4 SULFATE ION HOH water SO4 1150 3 SO4 SO4 1150 A HOH 2001 4 HOH HOH 2001 A HOH 2002 4 HOH HOH 2002 A HOH 2003 4 HOH HOH 2003 A HOH 2004 4 HOH HOH 2004 A HOH 2005 4 HOH HOH 2005 A HOH 2006 4 HOH HOH 2006 A HOH 2007 4 HOH HOH 2007 A HOH 2008 4 HOH HOH 2008 A HOH 2009 4 HOH HOH 2009 A HOH 2010 4 HOH HOH 2010 A HOH 2011 4 HOH HOH 2011 A HOH 2012 4 HOH HOH 2012 A HOH 2013 4 HOH HOH 2013 A HOH 2014 4 HOH HOH 2014 A HOH 2015 4 HOH HOH 2015 A HOH 2016 4 HOH HOH 2016 A HOH 2017 4 HOH HOH 2017 A HOH 2018 4 HOH HOH 2018 A HOH 2019 4 HOH HOH 2019 A HOH 2020 4 HOH HOH 2020 A HOH 2021 4 HOH HOH 2021 A HOH 2022 4 HOH HOH 2022 A HOH 2023 4 HOH HOH 2023 A HOH 2024 4 HOH HOH 2024 A HOH 2025 4 HOH HOH 2025 A HOH 2026 4 HOH HOH 2026 A HOH 2027 4 HOH HOH 2027 A HOH 2028 4 HOH HOH 2028 A HOH 2029 4 HOH HOH 2029 A HOH 2030 4 HOH HOH 2030 A HOH 2031 4 HOH HOH 2031 A HOH 2032 4 HOH HOH 2032 A HOH 2001 4 HOH HOH 2001 B HOH 2002 4 HOH HOH 2002 B HOH 2003 4 HOH HOH 2003 B HOH 2004 4 HOH HOH 2004 B HOH 2005 4 HOH HOH 2005 B HOH 2006 4 HOH HOH 2006 B SER 0 n 1 SER 0 A MET 1 n 2 MET 1 A THR 2 n 3 THR 2 A ASP 3 n 4 ASP 3 A CYS 4 n 5 CYS 4 A GLU 5 n 6 GLU 5 A PHE 6 n 7 PHE 6 A GLY 7 n 8 GLY 7 A TYR 8 n 9 TYR 8 A ILE 9 n 10 ILE 9 A TYR 10 n 11 TYR 10 A ARG 11 n 12 ARG 11 A LEU 12 n 13 LEU 12 A ALA 13 n 14 ALA 13 A GLN 14 n 15 GLN 14 A ASP 15 n 16 ASP 15 A TYR 16 n 17 TYR 16 A LEU 17 n 18 LEU 17 A GLN 18 n 19 GLN 18 A CYS 19 n 20 CYS 19 A VAL 20 n 21 VAL 20 A LEU 21 n 22 LEU 21 A GLN 22 n 23 GLN 22 A ILE 23 n 24 ILE 23 A PRO 24 n 25 PRO 24 A n 26 25 A n 27 26 A n 28 27 A n 29 28 A n 30 29 A n 31 30 A SER 31 n 32 SER 31 A LYS 32 n 33 LYS 32 A THR 33 n 34 THR 33 A SER 34 n 35 SER 34 A ARG 35 n 36 ARG 35 A VAL 36 n 37 VAL 36 A LEU 37 n 38 LEU 37 A GLN 38 n 39 GLN 38 A ASN 39 n 40 ASN 39 A VAL 40 n 41 VAL 40 A ALA 41 n 42 ALA 41 A PHE 42 n 43 PHE 42 A SER 43 n 44 SER 43 A VAL 44 n 45 VAL 44 A GLN 45 n 46 GLN 45 A LYS 46 n 47 LYS 46 A GLU 47 n 48 GLU 47 A VAL 48 n 49 VAL 48 A GLU 49 n 50 GLU 49 A LYS 50 n 51 LYS 50 A ASN 51 n 52 ASN 51 A LEU 52 n 53 LEU 52 A LYS 53 n 54 LYS 53 A SER 54 n 55 SER 54 A CYS 55 n 56 CYS 55 A LEU 56 n 57 LEU 56 A ASP 57 n 58 ASP 57 A ASN 58 n 59 ASN 58 A VAL 59 n 60 VAL 59 A ASN 60 n 61 ASN 60 A VAL 61 n 62 VAL 61 A VAL 62 n 63 VAL 62 A SER 63 n 64 SER 63 A VAL 64 n 65 VAL 64 A ASP 65 n 66 ASP 65 A THR 66 n 67 THR 66 A ALA 67 n 68 ALA 67 A ARG 68 n 69 ARG 68 A THR 69 n 70 THR 69 A LEU 70 n 71 LEU 70 A PHE 71 n 72 PHE 71 A ASN 72 n 73 ASN 72 A GLN 73 n 74 GLN 73 A VAL 74 n 75 VAL 74 A MET 75 n 76 MET 75 A GLU 76 n 77 GLU 76 A LYS 77 n 78 LYS 77 A GLU 78 n 79 GLU 78 A PHE 79 n 80 PHE 79 A GLU 80 n 81 GLU 80 A ASP 81 n 82 ASP 81 A GLY 82 n 83 GLY 82 A ILE 83 n 84 ILE 83 A ILE 84 n 85 ILE 84 A ASN 85 n 86 ASN 85 A TRP 86 n 87 TRP 86 A GLY 87 n 88 GLY 87 A ARG 88 n 89 ARG 88 A ILE 89 n 90 ILE 89 A VAL 90 n 91 VAL 90 A THR 91 n 92 THR 91 A ILE 92 n 93 ILE 92 A PHE 93 n 94 PHE 93 A ALA 94 n 95 ALA 94 A PHE 95 n 96 PHE 95 A GLU 96 n 97 GLU 96 A GLY 97 n 98 GLY 97 A ILE 98 n 99 ILE 98 A LEU 99 n 100 LEU 99 A ILE 100 n 101 ILE 100 A LYS 101 n 102 LYS 101 A LYS 102 n 103 LYS 102 A LEU 103 n 104 LEU 103 A LEU 104 n 105 LEU 104 A ARG 105 n 106 ARG 105 A GLN 106 n 107 GLN 106 A GLN 107 n 108 GLN 107 A ILE 108 n 109 ILE 108 A ALA 109 n 110 ALA 109 A PRO 110 n 111 PRO 110 A ASP 111 n 112 ASP 111 A VAL 112 n 113 VAL 112 A ASP 113 n 114 ASP 113 A THR 114 n 115 THR 114 A TYR 115 n 116 TYR 115 A LYS 116 n 117 LYS 116 A GLU 117 n 118 GLU 117 A ILE 118 n 119 ILE 118 A SER 119 n 120 SER 119 A TYR 120 n 121 TYR 120 A PHE 121 n 122 PHE 121 A VAL 122 n 123 VAL 122 A ALA 123 n 124 ALA 123 A GLU 124 n 125 GLU 124 A PHE 125 n 126 PHE 125 A ILE 126 n 127 ILE 126 A MET 127 n 128 MET 127 A ASN 128 n 129 ASN 128 A ASN 129 n 130 ASN 129 A THR 130 n 131 THR 130 A GLY 131 n 132 GLY 131 A GLU 132 n 133 GLU 132 A TRP 133 n 134 TRP 133 A ILE 134 n 135 ILE 134 A ARG 135 n 136 ARG 135 A GLN 136 n 137 GLN 136 A ASN 137 n 138 ASN 137 A GLY 138 n 139 GLY 138 A GLY 139 n 140 GLY 139 A TRP 140 n 141 TRP 140 A GLU 141 n 142 GLU 141 A ASN 142 n 143 ASN 142 A GLY 143 n 144 GLY 143 A PHE 144 n 145 PHE 144 A VAL 145 n 146 VAL 145 A LYS 146 n 147 LYS 146 A LYS 147 n 148 LYS 147 A PHE 148 n 149 PHE 148 A GLU 149 n 150 GLU 149 A ASP 141 n 1 ASP 141 B MET 142 n 2 MET 142 B ARG 143 n 3 ARG 143 B PRO 144 n 4 PRO 144 B GLU 145 n 5 GLU 145 B ILE 146 n 6 ILE 146 B TRP 147 n 7 TRP 147 B ILE 148 n 8 ILE 148 B ALA 149 n 9 ALA 149 B GLN 150 n 10 GLN 150 B GLU 151 n 11 GLU 151 B LEU 152 n 12 LEU 152 B ARG 153 n 13 ARG 153 B ARG 154 n 14 ARG 154 B ILE 155 n 15 ILE 155 B GLY 156 n 16 GLY 156 B ASP 157 n 17 ASP 157 B GLU 158 n 18 GLU 158 B PHE 159 n 19 PHE 159 B ASN 160 n 20 ASN 160 B ALA 161 n 21 ALA 161 B TYR 162 n 22 TYR 162 B TYR 163 n 23 TYR 163 B ALA 164 n 24 ALA 164 B ARG 165 n 25 ARG 165 B 4.2234 0.0842 0.9229 2.9115 -0.0071 1.3450 0.2037 0.1462 -0.1986 -0.3558 -0.1641 0.0423 -0.0705 -0.0767 -0.0396 -0.0312 0.0533 0.0299 -0.1180 0.0149 -0.1535 refined -5.5900 20.2230 52.3430 X-RAY DIFFRACTION A 0 A 149 X-RAY DIFFRACTION 1 B 141 B 165 X-RAY DIFFRACTION 1 author_and_software_defined_assembly PQS 2 dimeric 2770 -22.6 10260 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 A HOH 2019 D HOH 1 A CG MET 1 A CG MET 2 1 Y 1 A SD MET 1 A SD MET 2 1 Y 1 A CE MET 1 A CE MET 2 1 Y 1 A GLN 25 A GLN 26 1 Y 1 A PRO 26 A PRO 27 1 Y 1 A GLY 27 A GLY 28 1 Y 1 A SER 28 A SER 29 1 Y 1 A GLY 29 A GLY 30 1 Y 1 A PRO 30 A PRO 31 1 Y 1 A THR 114 -62.07 5.89 37.38 -0.24000 -0.12000 0.00000 -0.24000 0.00000 0.36000 0.947 0.902 HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS. RESIDUES 25-30 ARE DISORDERED, FIRST SER IS FROM VECTOR. 0.250 0.194 0.196 2.20 20.00 503 10075 4.800 99.9 10.977 0.137 RANDOM LIKELY RESIDUAL 1 THROUGHOUT MAD 0.250 0.211 0.80 0.80 1.20 NONE MAXIMUM LIKELIHOOD MASK 2.20 20.00 38 1436 5 0 1393 0.014 0.022 1423 1.401 1.939 1920 5.748 5.000 166 35.804 24.545 77 15.772 15.000 254 19.945 15.000 10 0.096 0.200 207 0.006 0.020 1083 0.209 0.200 715 0.308 0.200 1012 0.131 0.200 52 0.178 0.200 44 0.144 0.200 9 0.852 1.500 872 1.387 2.000 1353 2.157 3.000 652 3.307 4.500 567 0.2470 0.1930 2.26 40 708 20 2.20 20.00 2VM6 10576 2.0 0.066 1 30.27 11.7 99.7 0.52 2.20 2.30 4.75 1 8.9 100.0 refinement REFMAC 5.3.0040 data reduction XDS data scaling XSCALE phasing SOLVE BCL-2-RELATED PROTEIN A1, BCL-2-LIKE PROTEIN 11 Human Bcl2-A1 in complex with Bim-BH3 peptide 1 N N 2 N N 3 N N 4 N N 4 N N A SER 0 A SER 1 HELX_P A LEU 21 A LEU 22 1 1 22 A SER 31 A SER 32 HELX_P A LEU 52 A LEU 53 1 2 22 A LEU 52 A LEU 53 HELX_P A ASP 57 A ASP 58 1 3 6 A SER 63 A SER 64 HELX_P A GLU 80 A GLU 81 1 4 18 A ASN 85 A ASN 86 HELX_P A GLN 107 A GLN 108 1 5 23 A VAL 112 A VAL 113 HELX_P A THR 114 A THR 115 5 6 3 A TYR 115 A TYR 116 HELX_P A ASN 137 A ASN 138 1 7 23 A GLY 138 A GLY 139 HELX_P A GLY 143 A GLY 144 1 8 6 A GLY 143 A GLY 144 HELX_P A GLU 149 A GLU 150 1 9 7 B ARG 143 B ARG 3 HELX_P B TYR 163 B TYR 23 1 10 21 IMMUNE SYSTEM B-CELL LYMPHOMA2, ANTIAPOPTOTIC, IMMUNE SYSTEM, BIM, BFL-1, BCL2A1, BCL-2A1, MEMBRANE, APOPTOSIS 2VM6 PDB 1 2VM6 B2LA1_HUMAN UNP 1 Q16548 BIM_HUMAN UNP 2 O43521 0 0 2VM6 0 0 2VM6 A 1 1 1 1 149 2VM6 1 149 Q16548 A 2 2 150 141 165 2VM6 141 165 O43521 B 3 1 25 BINDING SITE FOR RESIDUE SO4 A1150 Software 3 A LYS 147 A LYS 148 3 1_555 B ALA 164 B ALA 24 3 1_555 B ARG 165 B ARG 25 3 1_555 155 H 3 2